Table 1.
Demographics of the study population by ZNF331 promoter methylation status.
| Methylated (N = 267) |
Unmethylated (N = 118) |
Total (N = 385) |
p-valuea | |
|---|---|---|---|---|
| Age | 0.01 | |||
| Median (Years) | 63.0 | 59.0 | 62.0 | |
| Q1, Q3 (Years) | 54.0, 70.0 | 51.0, 67.0 | 53.0, 69.0 | |
| Sex | 0.71 | |||
| Male | 148 (55.4%) | 63 (53.4%) | 211 (54.8%) | |
| Female | 119 (44.6%) | 55 (46.6%) | 174 (45.2%) | |
| Performance Status | 0.53 | |||
| 0 | 203 (76.6%) | 93 (79.5%) | 296 (77.5%) | |
| 1–2 | 62 (23.4%) | 24 (20.5%) | 86 (22.5%) | |
| Missing | 2 | 1 | 3 | |
| Treatment Arm | 0.34 | |||
| FU/LV | 134 (50.2%) | 53 (44.9%) | 187 (48.6%) | |
| IFL | 133 (49.8%) | 65 (55.1%) | 198 (51.4%) | |
| Tumor Site | <0.0001 | |||
| Distal | 173 (65.8%) | 46 (39.3%) | 219 (57.6%) | |
| Proximal | 90 (34.2%) | 71 (60.7%) | 161 (42.4%) | |
| Missing | 4 | 1 | 5 | |
| T-Stage | 0.31 | |||
| T1/T2 | 21 (8.0%) | 15 (12.9%) | 36 (9.5%) | |
| T3 | 222 (84.1%) | 93 (80.2%) | 315 (82.9%) | |
| T4 | 21 (8.0%) | 8 (6.9%) | 29 (7.6%) | |
| Missing | 3 | 2 | 5 | |
| Number of Nodes Sampled | 0.28 | |||
| Median | 13.0 | 12.0 | 13.0 | |
| Q1, Q3 | 9.0, 19.0 | 8.0, 17.0 | 9.0, 18.0 | |
| Missing | 2 | 1 | 3 | |
| Number of Positive Nodes | 0.89 | |||
| Median | 3.0 | 3.0 | 3.0 | |
| Q1, Q3 | 1.0, 5.0 | 1.0, 5.0 | 1.0, 5.0 | |
| Missing | 2 | 1 | 3 | |
| Extramural Vascular Invasion | 0.58 | |||
| Absent | 233 (90.3%) | 105 (92.1%) | 338 (90.9%) | |
| Present | 25 (9.7%) | 9 (7.9%) | 34 (9.1%) | |
| Missing | 9 | 4 | 13 | |
| Perineural Invasion | 0.84 | |||
| Absent | 241 (92.3%) | 105 (92.9%) | 346 (92.5%) | |
| Present | 20 (7.7%) | 8 (7.1%) | 28 (7.5%) | |
| Missing | 6 | 5 | 11 | |
| Lymphovascular Invasion | 0.70 | |||
| Absent | 177 (67.6%) | 80 (69.6%) | 257 (68.2%) | |
| Present | 85 (32.4%) | 35 (30.4%) | 120 (31.8%) | |
| Missing | 5 | 3 | 8 | |
| Histologic Grade | 0.99 | |||
| Grade 1/2 | 201 (76.1%) | 89 (76.1%) | 290 (76.1%) | |
| Grade 3/4 | 63 (23.9%) | 28 (23.9%) | 91 (23.9%) | |
| Missing | 3 | 1 | 4 | |
| MMR Status | 0.07 | |||
| pMMR | 216 (85.0%) | 102 (91.9%) | 318 (87.1%) | |
| dMMR | 38 (15.0%) | 9 (8.1%) | 47 (12.9%) | |
| Missing | 13 | 7 | 20 | |
| BRAFV600E | 0.003 | |||
| Wildtype | 207 (81.5%) | 103 (93.6%) | 310 (85.2%) | |
| Mutant | 47 (18.5%) | 7 (6.4%) | 54 (14.8%) | |
| Missing | 13 | 8 | 21 | |
| KRASmutation | 0.049 [2] | |||
| Wildtype | 160 (63.0%) | 81 (73.6%) | 241 (66.2%) | |
| Mutant | 94 (37.0%) | 29 (26.4%) | 123 (33.8%) | |
| Missing | 13 | 8 | 21 | |
| TP53mutation | 0.17 | |||
| Wildtype | 113 (61.1%) | 45 (52.3%) | 158 (58.3%) | |
| Mutant | 72 (38.9%) | 41 (47.7%) | 113 (41.7%) | |
| Missing | 82 | 32 | 114 | |
| CIMP Status | <0.0001 | |||
| CIMP– | 184 (69.2%) | 113 (97.4%) | 297 (77.7%) | |
| CIMP+ | 82 (30.8%) | 3 (2.6%) | 85 (22.3%) | |
| Missing | 1 | 2 | 3 | |
ap-values were calculated by χ2 test for all categorical variables, and Kruskal-Wallis test for continuous variables (i.e., Age, Number of Nodes Sampled, and Number of Positive Nodes).